Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. jointly filed a Schedule 13G reporting passive ownership of 4,200,950 Codexis (CDXS) common shares as of 30 Jun 2025. The position equals 5.07 % of outstanding stock, making the firms a 5-percent beneficial owner under SEC rules.
The filing states shared voting and dispositive power over the entire stake; neither entity holds sole authority. Aberdeen is classified as a parent holding company/control person (HC) incorporated in the United Kingdom, while abrdn Inc. is a U.S. corporation and registered investment adviser (CO, IA). Both certify the shares were acquired in the ordinary course of business and not to influence control of Codexis.
Signatures were provided by Major Shareholding Reporting Analyst Jenny Clarke on 30 Jul 2025. No exhibits indicate activist intent, group formation, or additional derivatives. The disclosure primarily informs investors of a new institutional holder exceeding the 5 % threshold, adding visibility to Codexis’ shareholder base without signaling governance changes.